Australia to review way chemotherapy is funded

7 May 2013

Australia’s Minister for Health Tanya Plibersek has announced a major review into the way chemotherapy is funded and provided as a way of ensuring the nation’s cancer patients have continued access to quality, affordable treatment.

“Being diagnosed and treated for cancer is a traumatic experience for patients and their families,” Ms Plibersek said, adding: “The Gillard government wants to ensure cancer patients don’t experience any interruption in their treatment while we closely examine how much we should be paying to support the ongoing viability for chemotherapy providers.”

Ms Plibersek said the review followed talks between the government and the Pharmacy Guild of Australia over appropriate subsidies for dispensing chemotherapy after the reduction in price the government pays for a key chemotherapy drug, docetaxel.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Generics